Old Web
English
Sign In
Acemap
>
authorDetail
>
Brad Sumrow
Brad Sumrow
Pathology
Medicine
Oncology
Internal medicine
in patient
3
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
2020
Journal of Clinical Oncology
Jason J. Luke
Manish R. Patel
Erika Paige Hamilton
Bartosz Chmielowski
Susanna Varkey Ulahannan
Hedy L. Kindler
Shakeela Wazeen Bahadur
Philip R. Clingan
Girish Mallesara
Andrew J. Weickhardt
Scott Currence
Linzhi Xu
Sanjeev Kaul
Francine Chen
Paul A. Moore
Ezio Bonvini
Brad Sumrow
George R. Blumenschein
Show All
Source
Cite
Save
Citations (12)
Immunohistochemistry analyses of LAG-3 expression across different tumor types and co-expression with PD-1.
2020
Journal of Clinical Oncology
Francine Chen
Thomas Sherwood
Anushka De Costa
Nicholas Yee-Toy
Peter Lung
Ann Easton
Brad Sumrow
Ezio Bonvini
Paul A. Moore
Show All
Source
Cite
Save
Citations (3)
A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.
2019
Journal of Clinical Oncology
Jason J. Luke
Manish Sharma
Rachel E. Sanborn
Gregory M. Cote
Johanna C. Bendell
Glen J. Weiss
Alexey Berezhnoy
Sharad K. Sharma
Paul A. Moore
Ezio Bonvini
Kerri Cali
Jan Baughman
Jon M. Wigginton
Brad Sumrow
Show All
Source
Cite
Save
Citations (0)
1